31 Using a 3D Fiducial Marker System to Advance the Use of 3D Accelerated Partial Breast Irradiation

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 40

Lori Anthony, PA1

1JFK Medical Center, Lake Worth, FL.

Background

Currently, no reliable techniques are available to accurately identify a lumpectomy cavity volume, creating difficulty for radiation oncologists in targeting the cavity volume as part of a treatment regimen. As such, oncologists must expand the planned target volume using a larger area or volume of radiation, which exposes a greater volume of normal tissue and makes it unclear if the postoperative tumor bed cavity has been treated with the intended goal.

Materials and Methods

A metallic marker woven inside a dissolvable suture was positioned in the lumpectomy cavity at time of surgery by the operating surgeon for pinpoint accuracy. After removal of the tumor, 4 to 6 sutures were placed in the wall of the cavity (superior, inferior, medial, lateral, anterior, and posterior).

During the 6- to 8-week period following surgery, weekly orthogonal kilovoltage images were acquired using the Varian Onboard Imager system and compared with orthogonal digitally reconstructed radiographs generated from the simulation CT. The matched image sets were then overlaid for verification of fiducial position relative to the surgical cavity by the radiation oncologist.

Results

During clinical trials, all safety and performance end points of the human study were met as intended, as follows:

  • No study subjects reported any adverse effects: pain, inflammation, infection, or tissue reaction with implantation of the markers.
  • The Accusyte 3D Fiducial Marker system demonstrated ability to stay on site and to produce accurate localization and excellent visualization as provided by the 3D approach.
  • All 98 radiographic images obtained during the study were clear, allowing for optimal localization and easy visualization of markers without any significant migration from initial target site.
  • Images taken 1-year post implantation showed that markers hadn’t moved and were clearly visible in radiography.
  • Surgical Radiation Products is continuing third year of follow-up with mammographic images, and again visualization of the markers without significant migration from initial site has been confirmed.
  • The Accusyte suture will eventually dissolve, leaving the markers for a lifetime of follow-up.

Conclusions

Use of a 3D Fiducial Marker will allow accurate visualization and delineation of the cavity volume with high degree of consistency and reliability. The Accusyte 3D Fiducial Marker system has eliminated the localization problem. The markers offer a precise, stable target for postoperative radiation. They are more effective than loose markers, clips, or other competitive products.

Expert Commentary

Expert Commentary

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients